

CONTACT

+1- 215-648-1208 Ext. 712

asalzman@thebrackengroup.com

www.linkedin.com/in/andrew-salzman-74608a8//

www.thebrackengroup.com

EDUCATION

- **Bachelor of Arts; 1979**
Yale College; Psychology;
Magna cum Laude
- **MD; 1983**
Harvard Medical School

ACADEMIC MEDICAL POSITIONS

- **University of Cincinnati College of Medicine**
Assistant Professor of Pediatrics and Molecular and Cellular Physiology; 1997-1999
- **Division of Critical Care Medicine, Children's Hospital Medical Center**
Founding Director; 1994-1998

Assistant Professor of Pediatrics; 1994 - 1997

MEDICAL BOARD CERTIFICATION

- **American Board of Pediatrics**
#35899; 1987
- **Diplomat; American Academy of Pediatrics, Critical Care Medicine**
1994

PROFESSIONAL SUMMARY

40 years' experience in the biotech/pharmaceutical industry having initiated and built several biotech companies. Harvard trained board certified in pediatrics specifically critical care and infectious disease. One of the greatest achievements was the discovery and development of the first PARP inhibitor for the treatment of cancer. Instrumental in identifying and developing the first adenosine 1 receptor agonist for use in ophthalmic.

PROFESSIONAL EXPERIENCE

2021 – The Bracken Group

Present Partner

2008– Salzman Group, Ltd. (Formerly Salzman Capital Ventures, Ltd.)

Present Chairman, Founder, Owner

- Founded and leads a 90-person Israeli company to provide capital and operational services to a global biotechnology, medical device, and pharmaceutical enterprises
- Leads consulting services to start-up, mid-sized pharmaceutical, and strategic pharmaceutical and agrochemical firms
- Built and manages a 16,000 square foot research and development facility in Katzrin
- Brokered venture capital raises of \$7 million and received contractual research service orders for \$90 million in the fields of medicinal chemistry, *in vitro* and *in vivo* pharmacology, scale-up process research and manufacturing, ADME/PK investigation, and clinical trials design and management.

2008- Salzman Group, Inc. (Formerly Radikal Therapeutics, Inc.)

Present Chairman, Founder, Owner

- Leads a 25-person Massachusetts pharmaceutical biotechnology firm that invents and develops therapeutics for inflammation, reperfusion injury, cardiovascular, and auto-immune disease.
- Invented 7 pre-clinical pharmaceutical assets, including a novel thioredoxin mimetic for treatment of acute lung injury, a novel potassium-ATP channel opener for treatment of hemorrhagic shock, and a novel redox degradation catalyst and nitric oxide donor for treatment of acute lung injury.
- Led raises totaling \$111 million
- Built out operations in a 9,000 square foot lab in Massachusetts

2014 - 2018 Salzman Investments, Ltd. (Formerly Salzman Lovelace Investments Ltd.)

Chairman, Founder

- A biotechnology firm focused on discovery and development of Resolvins, a novel class of anti-inflammatory lipid mediators, intended for inhalational treatment of cystic fibrosis, asthma, and chronic obstructive pulmonary disease. Advanced Phase 2 ready asset by developing a novel efficient synthetic route for large scale production of Resolvin E1.

FELLOWSHIPS

- **Beth Israel Hospital;** National Institute of Health Trauma Fellow; 1993 - 1994
- **Massachusetts General Hospital;** National Institute of Health Trauma Fellow; 1992 – 1993
- **University of Massachusetts Medical Center;** National Institute of Health Trauma Fellow; 1991 – 1992
- **Division of Neonatal and Pediatric Intensive Care, Massachusetts General Hospital;** Clinical Fellow in Neonatology; 1990 – 1992
- **Division of Neonatal and Pediatric Intensive Care, Massachusetts General Hospital;** Clinical Fellow in Pediatric Critical Care Medicine; 1990 – 1992
- **Division of Infectious Diseases, Children’s Hospital Medical Center;** Clinical Fellow in Pediatric Medicine; 1987 – 1989
- **Department of Chemical Immunology, Macarther Center for Tropical Disease, Weizman Institute of Science;** Whitman – Richardson Harvard Medical School Fellow; 1986 – 1987
- **Babies Hospital, Columbia – Presbyterian Medical Center ,** Pediatric Resident; 1984 – 1986
- **Babies Hospital, Columbia – Presbyterian Medical Center;** Pediatric Intern; 1983 – 1984
- **Goethe Institute;** German Academic Exchange Institute Fellow; 1980
- **Department of Child Psychiatry Hospital for Sick Children;** Psychiatric Research Fellow; 1977-1978

PROFESSIONAL EXPERIENCE

- 2017- Present** **Salzman Group Pty Ltd.**
Chairman, Founder
- 2018 - Present** **Herring Creek Pharmaceuticals, Inc.**
Chairman, Founder
- 2021 - Present** **SyncaLabs AG**
Chairman, Founder, Owner
- 2018 - 2020** **AOX Pharma**
Chairman, Founder
- 2017 - 2018** **Kalytera Therapeutics, Inc.; Kalytera Therapeutics, Ltd.**
Founder, Chief Executive Officer, Chief Medical Officer
- 2015 - 2018** **Tisbury Pharmaceuticals**
Chairman, Founder
- 2012 - 2017** **Lovelace Biomedical Research Institute**
Senior Fellow and Founding Director of Drug Development
- 2010 - 2013** **Orphan Technologies, Inc.**
Chairman, Founder, General Partner
- 2008 - 2012** **Luria Scientific Industries Limited**
Chairman, Founder, Owner
- 2008 - 2010** **Neopharm Life Sciences Ventures, Ltd.**
Chairman, Founder, General Partner

MEDICAL LICENSURE

South Carolina #19878

Ohio #66755

Massachusetts #59180

New York State #162426

LANGUAGES AND AWARDS

Fluency in English, German

Proficiency in French, Hebrew, Swiss-German

Yale University German Award, 1979

Society of Critical Care Medicine Educational Scholarship Award, 1993

SCIENTIFIC ACHIEVEMENTS AND PUBLICATIONS

170+ Publications, 46 Patents, 30+ Major Scientific and Medical Accomplishments